Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

New prostate drug licensed for UK use

  • Comment

A duel treatment pill for enlarged prostate patients has been approved for use in the UK.

Marketed as Combodart by GlaxoSmithKline, it is the first fixed dose combination therapy for treatment of benign prostatic hyperplasia.

It contains dutasteride 0.5mg and tamsulosin hydrochloride 0.4mg. Dutasteride delays progression of the disease by inhibiting the production of the male hormone dihydrotestosterone (DHT) that stimulates prostate growth, whilst tamsulosin provides symptom relief by reducing smooth muscle tone in the prostate and bladder neck.

Dr Jon Rees, a Bristol GP with a special interest in urology, said: “By combining the medication that targets the underlying cause of the disease with one that relieves symptoms fairly quickly, patients will be more likely to keep taking their medication, which in turn will decrease the risk of disease progression or patients requiring emergency surgery.”

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.